PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.88%
Revenue growth under 50% of META's 12.29%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
4.24%
Gross profit growth under 50% of META's 12.33%. Michael Burry would be concerned about a severe competitive disadvantage.
12.91%
EBIT growth 1.25-1.5x META's 10.27%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
12.91%
Operating income growth at 75-90% of META's 16.44%. Bill Ackman would demand a plan to enhance operating leverage.
-70.35%
Negative net income growth while META stands at 10.17%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-39.10%
Negative EPS growth while META is at 10.47%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-39.80%
Negative diluted EPS growth while META is at 11.04%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.09%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.08%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-2.87%
Negative OCF growth while META is at 6.39%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
1.21%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
2179.42%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
830.96%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
161.00%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
1963.31%
5Y OCF/share CAGR above 1.5x META's 653.02%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
183.19%
3Y OCF/share CAGR 1.25-1.5x META's 125.05%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
538.84%
Below 50% of META's 2770.56%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1084.29%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-9.72%
Negative 3Y CAGR while META is 194.47%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
3815.49%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
163.41%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.96%
AR growth is negative/stable vs. META's 14.10%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
156.82%
Inventory growth of 156.82% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
3.12%
Asset growth at 50-75% of META's 5.19%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
2.87%
Under 50% of META's 5.80%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
4.08%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-9.70%
We cut SG&A while META invests at 12.01%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.